Small intestinal bacterial overgrowth in irritable bowel syndrome: Are there any predictors?

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Reddymasu, Savio C ^a   Sostarich, Sandra ^a   McCallum, Richard W ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYDROGEN; METHANE; NARCOTIC ANALGESIC AGENT; PROTON PUMP INHIBITOR; TEGASEROD;

ADULT; AGE; AGED; ARTICLE; BACTERIAL OVERGROWTH; BLOATING; BREATH ANALYSIS; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; FEMALE; FLATULENCE; GENDER; GLUCOSE BREATH TEST; HUMAN; INGESTION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PREDICTION; SMALL INTESTINE BACTERIAL OVERGROWTH; GAS; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; SMALL INTESTINE; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLATULENCE; GASES; HUMANS; HYDROGEN; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME; LOGISTIC MODELS; MALE; METHANE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 77649299288     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-23     Document Type: Article

References (36)

1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(11 suppl):S1-S5. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force.
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131. 10.1053/gast.2002.37095, 12454866.
3. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 119:654-660. 10.1053/gast.2000.16484, 10982758.
4. Cash B, Sullivan S, Barghout V. Total costs of IBS: employer and managed care perspective. Am J Manag Care 2005, 11(1 suppl):S7-S16.
5. Dean BB, Aguilar D, Barghout V, Kahler KH, Frech F, Groves D, Ofman JJ. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005, 11(1 suppl):S17-S26.
6. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38:1569-1580. 10.1007/BF01303162, 8359066.
7. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004, 10:299-309.
8. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004, 292:852-858. 10.1001/jama.292.7.852, 15316000.
9. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005, 51(suppl 1):1-22. 10.1159/000081988, 15855746.
10. Simrén M, Stotzer P-O. Use and abuse of hydrogen breath tests. Gut 2006, 55:297-303. 10.1136/gut.2005.075127, 1856094, 16474100.
11. Di Stefano M, Corazza GR. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. Chemotherapy 2005, 51(suppl 1):103-109. 10.1159/000081996, 15855754.
12. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 2004, 7:19-28. 10.1007/s11938-004-0022-4, 14723835.
13. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22:1157-1160. 10.1111/j.1365-2036.2005.02690.x, 16305730.
14. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 21:1391-1395. 10.1111/j.1365-2036.2005.02493.x, 15932370.
15. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
16. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-d-xylose and healthy controls. Am J Gastroenterol 2005, 100:1566-1570. 10.1111/j.1572-0241.2005.40795.x, 15984983.
17. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506. 10.1111/j.1572-0241.2000.03368.x, 11151884.
18. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000, 14:551-556. 10.1046/j.1365-2036.2000.00751.x, 10792117.
19. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000, 14:1001-1008. 10.1046/j.1365-2036.2000.00808.x, 10930893.
20. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 22:31-35. 10.1111/j.1365-2036.2005.02516.x, 15963077.
21. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007, 52:139-142.
22. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007, 333:266-270. 10.1097/MAJ.0b013e3180536784, 17505166.
23. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006, 145:557-563.
24. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326-333. 10.1111/j.1572-0241.2006.00458.x, 16454838.
25. Lee H-R, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2006, 8:305-311. 10.1007/s11894-006-0051-3, 16836942.
26. Posserud I, Stotzer P-O, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007, 56:802-808. 10.1136/gut.2006.108712, 17148502.
27. Parisi G, Leandro G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, Pantalena M, Tafner G, Verdianelli G, Zilli M, . The AISGE Group Small intestinal bacterial overgrowth and irritable bowel syndrome. Am J Gastroenterol 2003, 98:2572. 10.1016/S0002-9270(03)01719-2, 14638371, The AISGE Group.
28. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005, 34:189-204. 10.1016/j.gtc.2005.02.008, 15862929.
29. Elphick HL, Elphick DA, Sanders DS. An underrecognized cause of malnutrition in older adults. Geriatrics 2006, 61:21-26.
30. Mitsui T, Shimaoka K, Goto Y, Kagami H, Kinomoto H, Ito A, Kondo T. Small bowel bacterial overgrowth is not seen in healthy adults but is in disabled older adults. Hepatogastroenterology 2006, 53:82-85.
31. Parlesak A, Klein B, Schecher K, Bode JC, Bode C. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc 2003, 51:768-773. 10.1046/j.1365-2389.2003.51259.x, 12757562.
32. Elphick DA, Chew TS, Higham SE, Bird N, Ahmad A, Sanders DS. Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier?. Gerontology 2005, 51:396-401. 10.1159/000088704, 16299421.
33. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003, 63:649-671. 10.2165/00003495-200363070-00003, 12656645.
34. Degen L, Petrig C, Studer D, Schroller S, Beglinger C. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005, 17:821-826. 10.1111/j.1365-2982.2005.00715.x, 16336497.
35. Williams C, McColl KEL. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006, 23:3-10. 10.1111/j.1365-2036.2006.02707.x, 16393275.
36. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. Am J Gastroenterol 2008, 103:2972-6. 10.1111/j.1572-0241.2008.01992.x, 19086951.